retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Targeting GLP-1, & GCG in and Type Diabetes Research Retatrutide Phase 3: 28.7% Weight

Clinical Trials: The Primary Access Route Enrolling in a TRIUMPH trial is the only way to receive pharmaceutical-grade retatrutide under medical supervision

Tirzepatide , on the other hand, is a dual agonist

Safety, tolerability, and proof-of-concept study of OKV-119, a novel exenatide long-term drug delivery system, in healthy Cats

Clinical trials over 56 weeks have shown that individuals taking Contrave, on average, lose significantly more weight compared to those who only engage in diet and exercise

The insulin-deficient Streptozotocin model (T1DM-like) was selected to investigate diabetes-induced neurocognitive impairment, with an emphasis on mechanisms driven by hyperglycaemia and neuroinflammation rather than on a specific diabetes subtype [23,24]

Additionally, about 6.8% of patients discontinue GLP-1 treatment due to side effects, primarily gastrointestinal issues